EGFR mutations are a standard prognostic biomarker when treating patients with advanced NSCLC with first-line EGFR tyrosine-kinase inhibitors (Mok et al., 2015; Zhang et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.